ASAS-OMERACT 中轴型脊柱关节炎核心结局域集更新
该研究依据 OMERACT 与 COMET 指南,由国际工作组通过系统文献综述、定性研究、三轮 Delphi 调查、ASAS 投票及 OMERACT 认可,将强直性脊柱炎核心结局集更新为中轴型脊柱关节炎核心域集,包含 7 个所有试验必选域,以及针对不同治疗类型的附加域。
要点
- 所有试验必选 7 域:疾病活动度、疼痛、晨僵、疲劳、躯体功能、整体功能与健康、不良事件(含死亡)。
- 改善病情疗法试验须加选 3 域:骨骼外表现、外周表现、结构损伤;症状改善疗法为重要但可选。
- 脊柱活动度、睡眠、工作与就业为所有试验重要但可选域。
核心结论
- ASAS-OMERACT 强直性脊柱炎核心结局集已更新为中轴型脊柱关节炎核心域集。
研究设计与样本
- 依据 OMERACT 和 COMET 指南,国际工作组代表患者、风湿科医生、健康专业人员、制药行业及药品监管机构代表制定核心域集。
- 开发过程包括系统文献综述和定性研究识别候选域、三轮 Delphi 调查选择最相关域、ASAS 共识投票及 OMERACT 认可。
主要发现
- 更新后的核心域集包括 7 个所有试验必选域:疾病活动度、疼痛、晨僵、疲劳、躯体功能、整体功能与健康、不良事件(含死亡)。
- 另有 3 个域(骨骼外表现、外周表现、结构损伤)对改善病情疗法试验为必选,对症状改善疗法试验为重要但可选。
- 脊柱活动度、睡眠、工作与就业被定义为所有试验的重要但可选域。
关键数值与推荐
- 7 个必选域适用于所有试验:疾病活动度、疼痛、晨僵、疲劳、躯体功能、整体功能与健康、不良事件(含死亡)。
- 3 个附加域(骨骼外表现、外周表现、结构损伤)对改善病情疗法试验为必选,对症状改善疗法试验为重要但可选。
- 3 个域(脊柱活动度、睡眠、工作与就业)为所有试验重要但可选。
临床怎么用
- 设计 axSpA 临床试验时,所有试验须测量 7 个必选域;改善病情疗法试验还须测量骨骼外表现、外周表现和结构损伤。
- 症状改善疗法试验可选择测量骨骼外表现、外周表现和结构损伤,所有试验可选择测量脊柱活动度、睡眠、工作与就业。
局限性
- 下一步是为每个域选择测量工具,当前尚未确定具体测量工具。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The current core outcome set for ankylosing spondylitis (AS) has had only minor adaptations since its development 20 years ago. Considering the significant advances in this field during the preceding decades, an update of this core set is necessary. OBJECTIVE: To update the ASAS-OMERACT core outcome set for AS into the ASAS-OMERACT core outcome set for axial spondyloarthritis (axSpA). METHODS: Following OMERACT and COMET guidelines, an international working group representing key stakeholders (patients, rheumatologists, health professionals, pharmaceutical industry and drug regulatory agency representatives) defined the core domain set for axSpA. The development process consisted of: i) Identifying candidate domains using a systematic literature review and qualitative studies; ii) Selection of the most relevant domains for different stakeholders through a 3-round Delphi survey involving axSpA patients and axSpA experts; iii) Consensus and voting by ASAS; iv) Endorsement by OMERACT. Two scenarios are considered based on the type of therapy investigated in the trial: symptom modifying therapies and disease modifying therapies. RESULTS: The updated core outcome set for axSpA includes 7 mandatory domains for all trials (disease activity, pain, morning stiffness, fatigue, physical function, overall functioning and health, and adverse events including death). There are 3 additional domains (extra-musculoskeletal manifestations, peripheral manifestations and structural damage) that are mandatory for disease modifying therapies and important but optional for symptom modifying therapies. Finally, 3 other domains (spinal mobility, sleep, and work and employment) are defined as important but optional domains for all trials. CONCLUSION: The ASAS-OMERACT core domain set for AS has been updated into the ASAS-OMERACT core domain set for axSpA. The next step is the selection of instruments for each domain.
引用
- Navarro-Compán V, Boel A, Boonen A, et al. The ASAS-OMERACT core domain set for axial spondyloarthritis. Semin Arthritis Rheum. 2021. PMID: 34489113. doi:10.1016/j.semarthrit.2021.07.021
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。